ELOX

In a report released today, Andrew Fein from H.C. Wainwright maintained a Hold rating on Eloxx Pharmaceuticals (ELOX – Research Report), with a price target of $1.00. The company's shares closed last Wednesday at $0.57, close to its 52-week low of $0.37. According to TipRanks.com, Fein has 0 stars on 0-5 stars ranking scale with an average return of -3.6% and a 39.7% success rate. Fein covers the Healthcare sector, focusing on stocks such as DBV Technologies SA - American, Amylyx Pharmaceuticals Inc, and Deciphera Pharmaceuticals. The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Eloxx Pharmaceuticals with a $2.00 average price target.
https://www.tipranks.com/news/blurbs/h-c-wainwright-keeps-a-hold-rating-on-eloxx-pharmaceuticals-elox?utm_source=advfn.com&utm_medium=referral